St. John's Wort (Hypericum perforatum)

Hypericum perforatum
Evidence Level
Strong
2 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

St. John's Wort is a flowering plant with over 2,000 years of medicinal use and one of the most extensively studied herbal antidepressants. Its active compounds hypericin and hyperforin have demonstrated antidepressant effects comparable to standard pharmaceutical antidepressants in multiple meta-analyses — with a significantly better tolerability profile for mild to moderate depression. However, it is also among the most clinically significant herbal medicines for drug interactions, inducing CYP3A4 and P-glycoprotein to reduce blood levels of many commonly prescribed medications.

Studied Dose 300 mg three times daily (900 mg/day) standardized to 0.3% hypericin; some extracts standardized to 3–5% hyperforin; 4–6 weeks for full antidepressant effect
Active Compound Hypericin (0.3% standardized) and hyperforin (3–5% standardized) — Jarsin® 300 (Lichtwer Pharma) and LI 160 are the most clinically studied extracts

Mild to moderate depression treatment

The most comprehensive meta-analysis of St. John's Wort (29 RCTs, 5,489 patients) confirms it is significantly more effective than placebo and similarly effective to standard antidepressants (SSRIs, TCAs) for mild-to-moderate depression — with significantly fewer side effects and better tolerability. Particularly well-established in European clinical practice where it is licensed as a pharmaceutical in several countries.

Anxiety and stress reduction

Beyond depression, SJW demonstrates anxiolytic effects in clinical studies, reducing anxiety, irritability, and psychological stress. The mechanism involves GABAergic modulation and serotonin reuptake inhibition, producing calming effects that complement the antidepressant activity.

Seasonal affective disorder (SAD)

St. John's Wort is specifically effective for seasonal affective disorder (winter depression) — with RCT evidence showing comparable efficacy to light therapy. The photosensitizing hypericin may paradoxically benefit mood regulation via photosensitization-mediated retinal signaling.

Menopausal mood symptoms

Clinical trials in perimenopausal and menopausal women show SJW significantly improves mood, reduces irritability, and improves overall quality of life — with some studies showing improvements in hot flash frequency when combined with black cohosh (Klimadynon).

1

Multi-neurotransmitter reuptake inhibition

Hyperforin inhibits neuronal reuptake of serotonin, dopamine, norepinephrine, GABA, and glutamate simultaneously by activating sodium conductive transient receptor potential channel 6 (TRPC6) — a unique mechanism entirely different from SSRIs or SNRIs. This broad neurotransmitter modulation explains both the antidepressant efficacy and the mild anxiolytic effects.

2

HPA axis and cortisol normalization

SJW normalizes HPA axis hyperactivity in depression by reducing CRH and ACTH-stimulated cortisol hypersecretion — addressing a key biological abnormality in major depression. Hypericin specifically appears to modulate glucocorticoid receptor sensitivity, restoring normal cortisol feedback regulation.

3

CYP3A4 and P-glycoprotein induction

Hyperforin strongly induces CYP3A4, CYP2C9, and intestinal P-glycoprotein expression via pregnane X receptor (PXR) activation — dramatically increasing the metabolism and elimination of numerous medications. This mechanism underlies the most clinically significant herb-drug interactions in herbal medicine.

1
St. John's Wort vs. Antidepressants — Meta-Analysis of 29 RCTs
PubMed

Comprehensive meta-analysis of 29 RCTs (5,489 patients) comparing SJW to placebo and standard antidepressants for mild-to-moderate depression.

5,489 patients with mild to moderate depression across 29 RCTs.

SJW significantly more effective than placebo (RR 1.48). Comparable efficacy to standard antidepressants (RR 1.01). Significantly fewer patients dropped out due to adverse effects vs. antidepressants (0.8% vs. 3.0%). Established SJW as evidence-based treatment for mild-to-moderate depression.

2
St. John's Wort and Seasonal Affective Disorder — RCT
PubMed

Randomized, double-blind trial of SJW extract vs. light therapy vs. combination in 301 patients with seasonal affective disorder.

301 SAD patients. Winter season intervention.

SJW monotherapy equally effective to bright light therapy for SAD. Combination of SJW + light therapy showed trend toward greater improvement. Both treatments well-tolerated. Establishes SJW as effective SAD treatment.

Common Potential side effects

Photosensitivity — increased sensitivity to UV radiation; wear sunscreen, especially fair-skinned individuals at higher doses
GI upset, dry mouth, dizziness, fatigue in small percentage
Sexual dysfunction (reduced libido) at rates lower than SSRIs but still reported
Do NOT use for severe depression — evidence limited to mild-to-moderate; seek professional care for severe depression

Important Drug interactions

CRITICAL — MAJOR DRUG INTERACTIONS: SJW induces CYP3A4, CYP2C9, and P-glycoprotein, reducing blood levels of many medications:
Oral contraceptives — SJW can cause contraceptive failure leading to unintended pregnancy; avoid combination
HIV antiretrovirals (indinavir, nevirapine) — SJW markedly reduces drug levels; can lead to treatment failure
Cyclosporine (transplant rejection drug) — SJW reduces levels to sub-therapeutic; has caused transplant rejection
Warfarin — significantly reduced anticoagulation; INR drops; increased clotting risk
Digoxin — reduced levels; risk of cardiac decompensation
Antidepressants (SSRIs, MAOIs) — serotonin syndrome risk; never combine with MAOIs